Eli Lilly (LLY) rebounded off the long-term trendline and weekly demand box (≈622–686) and is compressing inside a descending wedge.
Bullish path (blue): a clean break and retest of wedge resistance opens room toward the prior extension/marker near ~970.
Bearish path (red): rejection at the wedge cap could send price back to the green trendline for a higher-low around ~685 before another attempt up.
News supporting the bullish path:
1- Mounjaro (tirzepatide) UK price hike: Lilly will lift UK list prices by up to ~170% from Sept 1, 2025 (e.g., highest doses from ~£122 to ~£330), with pharmacies flagging stockpiling/shortages. This supports revenue/ASP but may draw scrutiny.
2- Phase 3 ATTAIN-2 (orforglipron, oral GLP-1): trial met primary & key secondary endpoints in patients with obesity/overweight and Type-2 diabetes; company guiding to global regulatory submissions this year. Reports cite ~10.5% mean weight loss at the top dose. Sentiment tailwind for the obesity franchise.
Invalidation: weekly close below ~622.
Not financial advice :)
Bullish path (blue): a clean break and retest of wedge resistance opens room toward the prior extension/marker near ~970.
Bearish path (red): rejection at the wedge cap could send price back to the green trendline for a higher-low around ~685 before another attempt up.
News supporting the bullish path:
1- Mounjaro (tirzepatide) UK price hike: Lilly will lift UK list prices by up to ~170% from Sept 1, 2025 (e.g., highest doses from ~£122 to ~£330), with pharmacies flagging stockpiling/shortages. This supports revenue/ASP but may draw scrutiny.
2- Phase 3 ATTAIN-2 (orforglipron, oral GLP-1): trial met primary & key secondary endpoints in patients with obesity/overweight and Type-2 diabetes; company guiding to global regulatory submissions this year. Reports cite ~10.5% mean weight loss at the top dose. Sentiment tailwind for the obesity franchise.
Invalidation: weekly close below ~622.
Not financial advice :)
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。